Subcutaneous bispecific antibody cevostamab demonstrated early efficacy and safety in patients with relapsed or refractory multiple myeloma.
Andrea Eleazar, MHS
Advertisement
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Sub-Q Mosunetuzumab Wins FDA Approval in R/R Follicular Lymphoma
2
Opinion: CAR T-Cell Therapy Shows Promise in Gastric and GEJ Cancers
3
Real, Placebo Acupuncture Improve Cognitive Outcomes in Breast Cancer Survivors
4
FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications
5